Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.74 |
| ▸ | MEN1 | O00255 | 4/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.74 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.74 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.74 |
| ▸ | RELA | Q04206 | 3/20 | 0.74 |
| ▸ | PPP1CA | P62136 | 2/20 | 0.74 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.74 |
| ▸ | MBD2 | Q9UBB5 | 2/20 | 0.74 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.74 |
| ▸ | KCNN1 | Q92952 | 2/20 | 0.70 |
| ▸ | KCNN2 | Q9H2S1 | 2/20 | 0.70 |
| ▸ | KCNN3 | Q9UGI6 | 2/20 | 0.70 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.70 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.70 |
| ▸ | SLC2A1 | P11166 | 3/20 | 0.69 |
| ▸ | RAB9A | P51151 | 4/20 | 0.67 |
| ▸ | HTT | P42858 | 3/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13803792 | 0.86 | MAPT (0.78) | MAPTKMT2AMEN1SMN1; SMN2NFKB1 | |
| SCHEMBL30745718 | 0.86 | MAPT (0.69) | MAPTKMT2AMEN1SMN1; SMN2NFKB1 | |
| SCHEMBL27039811 | 0.86 | MAPT (0.69) | MAPTKMT2AMEN1SMN1; SMN2NFKB1 | |
| SCHEMBL12639826 | 0.86 | SMN1; SMN2 (1.00) | MAPTKMT2AMEN1SMN1; SMN2NFKB1 | |
| SCHEMBL13390238 | 0.85 | MBD2 (1.00) | MAPTKMT2AMEN1SMN1; SMN2NFKB1 | |
| SCHEMBL30060152 | 0.85 | MBD2 (1.00) | MAPTKMT2AMEN1SMN1; SMN2NFKB1 | |
| SCHEMBL5157963 | 0.83 | KCNN1 (1.00) | MAPTKMT2AMEN1SMN1; SMN2NFKB1 | |
| SCHEMBL29601716 | 0.83 | KCNN1 (1.00) | MAPTKMT2AMEN1SMN1; SMN2NFKB1 | |
| SCHEMBL7678939 | 0.82 | MAPT (0.81) | MAPTKMT2AMEN1SMN1; SMN2NFKB1 | |
| SCHEMBL23553573 | 0.82 | NPY5R (0.76) | MAPTKMT2AMEN1SMN1; SMN2NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105436-A1 | HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT | AUCKLAND UNISERVICES LIMITED (NZ) | 2011-05-05 | — | — | US | claimed |
| US-20110105436-A1 | HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT | AUCKLAND UNISERVICES LIMITED (NZ) | 2011-05-05 | — | — | US | disclosed |
| US-20110105436-A1 | HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT | AUCKLAND UNISERVICES LIMITED (NZ) | 2011-05-05 | — | — | US | disclosed |
| US-20110105436-A1 | HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT | AUCKLAND UNISERVICES LIMITED (NZ) | 2011-05-05 | — | — | US | disclosed |
| WO-2009114552-A1 | HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2009-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105436-A1 | HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT | VHL, TP53, BECN1 | MAPT 2506/4885KMT2A 2132/4885MEN1 3092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.